Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review

Single-port and multiport robot-assisted radical prostatectomy: A meta-analysis

“…Clinical management of PCa may vary significantly according to the age, tumor stage, risk stratification, hereditary predisposition, and patient's comorbidities 3 , 4 . Hence, managing this heterogeneous disease requires a multidisciplinary approach, including surgical, medical, and radiation oncology disciplines to apply the most appropriate treatment for these patients 5 , 6 .…”

The feasibility of distance to the tumor of biopsy cores to estimate the extracapsular extension

“…Furthermore, in active surveillance (AS), the precise staging of localized prostate cancer using prostate biopsy is essential to determine the suitability of AS for low-grade cases. 3 , 4 , 5 However, in nearly half of patients with clinically low-risk prostate cancer, the surgical pathology findings differ after prostatectomy. 6 , 7 Even in cases with intermediate-risk profiles based on a single positive biopsy core, there is a notable discordance of 37% and 58% in grading after prostatectomy.…”

Auraptene Enhances AMP-Activated Protein Kinase Phosphorylation and Thereby Inhibits the Proliferation, Migration and Expression of Androgen Receptors and Prostate-Specific Antigens in Prostate Cancer Cells

“…Prostate cancer is one of the most common cancers in men, with 1.41 million new cases in 2020 [1]. While several treatment options are available, including surgery, radiation, and anti-androgen therapy, another approach is expectant management, in which cancer progression is monitored without definitive therapy, reflecting how slow-growing prostate tumors tend to be [2][3][4]. Compared with the side effects of widely used cancer drugs, certain natural products with low toxicity levels might be beneficial and merit consideration for treatment and/or prevention of cancer development.…”